Analysts Offer Insights on Healthcare Companies: 3SBio (OtherTRSBF), UnitedHealth (UNH) and Caribou Biosciences (CRBU)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 3SBio (TRSBF – Research Report), UnitedHealth (UNH – Research Report) and Caribou Biosciences (CRBU – Research Report).

3SBio (TRSBF)

Morgan Stanley analyst Sean Wu CFA maintained a Hold rating on 3SBio today and set a price target of HK$7.50. The company’s shares closed last Wednesday at $0.80.

According to TipRanks.com, CFA is ranked #7976 out of 8786 analysts.

Currently, the analyst consensus on 3SBio is a Hold with an average price target of $1.02, which is a 27.5% upside from current levels. In a report issued on March 21, Goldman Sachs also maintained a Hold rating on the stock with a HK$8.52 price target.

See Insiders’ Hot Stocks on TipRanks >>

UnitedHealth (UNH)

In a report released today, Erin Wright from Morgan Stanley reiterated a Buy rating on UnitedHealth, with a price target of $584.00. The company’s shares closed last Thursday at $455.38, close to its 52-week low of $445.68.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 16.5% and a 68.0% success rate. Wright covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Elanco Animal Health, and Patterson Companies.

UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $588.25, representing a 27.7% upside. In a report released yesterday, Argus Research also maintained a Buy rating on the stock with a $570.00 price target.

Caribou Biosciences (CRBU)

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Buy rating on Caribou Biosciences, with a price target of $30.00. The company’s shares closed last Thursday at $4.54.

According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of 12.8% and a 46.2% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arvinas Holding Company, and Olema Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $22.00 average price target, implying a 361.2% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $17.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.